J1932, injection, lanreotide, (Cipla), has received Pass-Through Status G – 2/1/23

[et_pb_section fb_built=”1″ theme_builder_area=”post_content” _builder_version=”4.19.4″ _module_preset=”default”][et_pb_row _builder_version=”4.19.4″ _module_preset=”default” theme_builder_area=”post_content”][et_pb_column _builder_version=”4.19.4″ _module_preset=”default” type=”4_4″ theme_builder_area=”post_content”][et_pb_code _builder_version=”4.19.4″ _module_preset=”default” theme_builder_area=”post_content” hover_enabled=”0″ sticky_enabled=”0″] /* OUTLOOK-SPECIFIC STYLES */ li { text-indent: -1em; padding: 0; margin: 0; /* line-height: 1.2; Remove after testing */ } ul, ol { padding: 0; margin: 0 0 0 40px; } p { margin: 0; padding: 0; margin-bottom: 0; } J1932, injection, lanreotide, (Cipla), has received Pass-Through Status G from The Centers for Medicare and Medicaid (CMS)

From: BuyandBill.com <info@buyandbill.com

To: [customer]

Subject: J1932, Lanreotide Injection (Cipla) has received Pass-Through Status G from The Centers for Medicare and Medicaid (CMS)

Effective January 1, 2023:


J1932, injection, lanreotide, (Cipla), has received Pass-Through Status G from

The Centers for Medicare and Medicaid (CMS)1


HCPCS

Code

HCPCS Code

Descriptor

NDC

Number

How

Supplied

APC Per HCPCS Unit (1 mg)

HCPCS Units Per Package

J1932

injection, lanreotide, (Cipla), 1 mg

69097-0870-67

Lanreotide Acetate Subcutaneous Solution 120/MG/.05mL

$60.378

120


Please contact us @ Account.Management@Cipla.com


© Copyright 2023 Cipla USA Inc. All rights reserved


January 2023   CUSAI-09292022-01

References: 1. https://www.cms.gov/license/ama?file=/files/zip/january-2023-opps-addendum-b.zip